European Commission Approves Revolutionary First-Ever SMA Tablet Treatment: Roche's Evrysdi Changes Patient Care

Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy - Pharmafile

Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and only tablet available for the treatment of spinal muscular atrophy (SMA), a rare, genetic neuromuscular condition. The label extension allows the 5mg tablet to be used across the EU, offering an alternative to the existing […] The post Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy appeared first …

Key Clinical Considerations for the Management of SMA

Panelists discuss how disease progression despite treatment in older patients with spinal muscular atrophy (SMA) may be due to natural aging effects combined with SMA, not necessarily treatment failure, highlighting the importance of exercise, nutrition, and management of contractures.

European Commission Approves New Evrysdi Tablet, Offering Enhanced Flexibility for SMA Treatment

European Commission Approves New Evrysdi Tablet, Offering Enhanced Flexibility for SMA Treatment (IN BRIEF) Roche announced the European Commission’s approval of a label extension for Evrysdi® (risdiplam) to include a new 5mg tablet, offering a room-temperature stable alternative to the original oral solution for individuals with spinal muscular atrophy (SMA). The tablet, which can be taken whole or dissolved in water, provides the same proven e…

Roche extends SMA market lead with Evrysdi tablet approval in Europe - Pharmaceutical Technology

Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.

European Commission Approves Revolutionary First-Ever SMA Tablet Treatment: Roche's Evrysdi Changes Patient Care

New room-temperature stable Evrysdi tablet offers greater independence for SMA patients. First non-invasive option reaches 18,000+ globally. Learn more.